Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ACTRN12626001094369) titled 'Optisulin vs NovoMix30 insulin in pregnant women with gestational diabetes' on Sept. 4.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Masking: Open (masking not used)
Assignment: Parallel
Type of endpoint: Efficacy
Primary Sponsor: Canberra Hospital Department of Endocrinology
Condition:
Gestational diabetes
Gestational diabetes
Metabolic and Endocrine - Diabetes
Intervention:
Novomix30 (30% soluble insulin aspart (rys) and 70% insulin aspart (rys) crystallised with protamine) by subcutaneous injection before dinner for insulin requiring gestational...